On November 12, 2026, Intellia Therapeutics, Inc. (the “Company”) hosted a webcast for investors, analysts and others titled “Readying Lonvo-z for Patients with HAE.” A copy of the presentation presented at this event is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
|
Intellia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapeutics using CRISPR gene editing, oligonucleotides, and lipid nanoparticles. The company's lead product candidates are lonvoguran ziclumeran (lonvo-z) for hereditary angioedema and nexiguran ziclumeran (nex-z) for transthyretin amyloidosis, both of which are in Phase 3 clinical development as in vivo genome editing therapies. Intellia utilizes proprietary technologies to create single-dose, intravenous treatments designed to address the root causes of severe diseases. The company maintains a collaboration with Regeneron Pharmaceuticals to advance additional product candidates and is building a U.S.-focused commercial infrastructure to support the planned launch of its lead assets. Its research efforts focus on liver targets and expanding delivery technologies for diseases outside the liver. Summarised from the company's own disclosures, fiscal year ended Feb 2026 |
Industry Biotechnology | Homepage intelliatx.com |
| Sector Healthcare | IR page ir.intelliatx.com | |
|
Tags
crispr gene editing, in vivo gene editing, rare diseases, hereditary angioedema, transthyretin amyloidosis, lipid nanoparticles, oligonucleotides, clinical stage, lonvoguran ziclumeran, lonvo-z, NTLA-2002, nexiguran ziclumeran, nex-z, NTLA-2001, HAELO, Regeneron Pharmaceuticals
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 1.682B |
| Market cap (USD) | $ 1.682B |
| P/E | -3.60 |
| PEG | — |
| P/BV | 2.74 |
| P/S | 31.80 |
| P/OCF | -4.73 |
| P/FCF | -4.70 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -53.5% |
| ROI | -70.8% |
| ROIC | -56.8% |
| Profit margin | -609.9% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 12.0% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 58 |
| Quality score | -38.9% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.671M | 57.877M | 36.275M | 52.121M | 33.053M | 57.994M | 43.103M | 30.434M | — | — | — |
| Net profit | -412.694M | -519.021M | -481.192M | -474.186M | -267.892M | -134.231M | -99.533M | -85.343M | -67.543M | -31.634M | -12.397M |
| Free cash flow | -395.865M | -354.658M | -408.071M | -346.845M | -237.786M | -53.497M | -110.034M | -67.615M | -75.367M | 29.944M | -4.317M |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | 6.45M | 10.5M | 7.55M | 4.62M | 2.13M | 2.03M | 3.77M | 36.5M | 8.52M | 9.47M |
| ↳ YoY growth | +545.4% | +62.2% | -27.9% | -38.8% | -53.9% | -4.6% | +85.5% | +867.5% | -76.6% | +11.2% |
| ↳ 5y CAGR | +16.3% | -20.6% | -18.5% | +37.0% | +13.0% | +34.8% | ||||
| Borrowings, non-current (USD) | — | — | — | — | — | — | — | — | — | 0.00 |
| Lease liabilities (USD) | — | — | — | 18.4M | 39.3M | 74M | 131M | 115M | 210M | 93.3M |
| Cash and deposits (USD) | 273M | 341M | 58.9M | 57.2M | 160M | 123M | 524M | 227M | 189M | 155M |
| Right-of-use assets (USD) | — | — | — | 19.1M | 39.1M | 79.1M | 133M | 115M | 219M | 106M |
| Net debt (borrowings + leases - cash) (USD) | — | — | — | — | — | — | — | — | — | -62.1M |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | 36.1M | -65.3M | -61.3M | -103M | -49.9M | -225M | -333M | -394M | -349M | -395M |
| Purchases of property, plant and equipment (USD) | -6.17M | -10.1M | -6.36M | -6.79M | -3.59M | -12.8M | -13.6M | -14M | -5.78M | -1.13M |
| Change in receivables (cash effect) (USD) | -5.45M | -4.02M | 2.92M | 2.93M | 2.49M | 99,000 | -1.74M | -32.7M | 27.9M | -951,000 |
| Change in payables (cash effect) (USD) | 1.78M | -488,000 | 232,000 | 1.88M | 5.06M | 529,000 | -4.58M | 2.52M | 6.8M | 5.99M |
| Share-based compensation (USD) | 6.72M | 15.3M | 17M | 15.1M | 19.9M | 47M | 91.4M | 134M | 154M | 80.2M |
| Operating cash flow before change in receivables (USD) | 41.6M | -61.3M | -64.2M | -106M | -52.4M | -225M | -332M | -361M | -377M | -394M |
| Free cash flow (OCF - PPE - intangibles) (USD) | 29.9M | -75.4M | -67.6M | -110M | -53.5M | -238M | -347M | -408M | -355M | -396M |
| Income detail | ||||||||||
| Research and development expense (USD) | 31.8M | 67.6M | 89.1M | 108M | 150M | 230M | 420M | 435M | 466M | 389M |
| ↳ 5y CAGR | +68.2% | +48.5% | +44.1% | +37.3% | +33.9% | +20.9% | ||||
| Total comprehensive income (USD) | -31.6M | -67.5M | -85.4M | -99.2M | -134M | -271M | -479M | -476M | -518M | -412M |
| Comprehensive income to owners (USD) | -31.6M | -67.5M | -85.4M | -99.2M | -134M | -271M | -479M | -476M | -518M | -412M |
| Reported | Feb 27, 2019 | Feb 27, 2019 | Feb 27, 2019 | Feb 27, 2020 | Feb 26, 2021 | Feb 24, 2022 | Feb 23, 2023 | Feb 22, 2024 | Feb 27, 2025 | Nov 5, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
On November 12, 2026, Intellia Therapeutics, Inc. (the “Company”) hosted a webcast for investors, analysts and others titled “Readying Lonvo-z for Patients with HAE.” A copy of the presentation presented at this event is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
November 6, 2026
CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on November 1, 2026, it awarded inducement grants to three new employees as a material inducement to employment.
The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 12,900 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Investor Contact: Jason Fredette Vice President, Investor Relations and Corporate Communications Intellia Therapeutics, Inc. [email protected]
Media Contact: Mike Tattory Vice President LifeSci Communications [email protected]

Quick Links
PRINT PAGE
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Intellia Therapeutics, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| ARKG | 1.88% | 3,497,291 | $ 34.204M | Nov 18, 2026 |
| MEDX | 1.12% | 12,584 | $ 212.921K | Jun 30, 2026 |
| ARKK | 1.08% | 14,063,687 | $ 137.543M | Nov 18, 2026 |
| FSCC | 0.33% | 94,271 | $ 1.2M | Aug 31, 2026 |
| HRTS | 0.31% | 13,708 | $ 174.503K | Aug 31, 2026 |
| SEIS | 0.26% | 90,853 | $ 1.537M | Jun 30, 2026 |
| FSEV | 0.17% | 670 | $ 11.336K | Jun 30, 2026 |
| FESM | 0.10% | 344,292 | $ 5.825M | Jun 30, 2026 |
| RESM | 0.07% | 156 | $ 2,639.52 | Jun 30, 2026 |
| AVSC | 0.07% | 230,284 | $ 2.271M | Nov 16, 2026 |
| DFAS | 0.03% | 794,660 | $ 8.384M | Nov 12, 2026 |
| DXUV | 0.01% | 77,572 | $ 818.385K | Nov 12, 2026 |
| MSSM | 0.01% | 7,110 | $ 90.51K | Aug 31, 2026 |
| AVIE | 0.01% | 100 | $ 986.00 | Nov 16, 2026 |
| DFAC | 0.01% | 580,026 | $ 6.119M | Nov 12, 2026 |
| DCOR | 0.00% | 154,308 | $ 1.628M | Nov 12, 2026 |
| DFAU | 0.00% | 36,517 | $ 385.254K | Nov 12, 2026 |
| DFSU | 0.00% | 6,589 | $ 69.514K | Nov 12, 2026 |
| DFUS | 0.00% | 46,919 | $ 494.995K | Nov 12, 2026 |
| VFMO | 0.00% | 73 | $ 929.29 | Aug 31, 2026 |
| AVUS | 0.00% | 13,957 | $ 137.616K | Nov 16, 2026 |



















